Healthcare Innovations for Canadians

Valeo Pharma is committed to provide healthcare professionals and patients with innovative therapeutic solutions to improve quality of life.

ONSTRYV® NOW AVAILABLE IN CANADA

A new option for the treatment of Parkinson's Disease

Valeo Pharma is pleased to announce the launch of ONSTRYV® (safinamide tablets) in Canada.

Onstryv® (safinamide tablets) is the first new oral medication approved for Parkinson's Disease in Canada in over 10 years. Parkinson's Disease affects approximately 100,000 Canadians with approximately 6,600 new cases being diagnosed each year.

See full press release See product details

Products

Synacthen® Depot
M-Eslon
Onstryv
Utrogestan
Ethacrynate Sodium
Benztropine
Ondansetron

Business
Development

Valeo Pharma Inc. has built its business on a foundation of strong partnerships with Global pharmaceutical companies. We look for partners with world class R&D and state of the art manufacturing facilities to expand our own internal capabilities.

Capabilities

Valeo Pharma is a fully integrated Canadian Specialty Pharmaceutical company building successful strategic partnerships to deliver therapeutic solutions to Healthcare Professionals, and patients with unmet medical needs.

Newsroom

About Valeo Pharma

Driven by our experienced management team with in-depth knowledge of the Canadian market conditions and long-standing relationships with key industry leaders and healthcare professionals, our solid business model provides the required resources to successfully introduce specialty pharmaceutical products to Canada.

More